Literature DB >> 1638559

A modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis.

P D Ridley1, M H Yacoub, M J Curtis.   

Abstract

OBJECTIVE: The aim was to develop a simple modified global ischaemia preparation to study the relation between ischaemic zone size and the incidence of ischaemia induced and reperfusion induced arrhythmias, to test the hypothesis that arrhythmias are initiated by flow of injury current between the ischaemic zone and the uninvolved myocardium. The new model was used to examine whether injury current suppression is involved in the mechanism of action of a new antiarrhythmic intervention, substitution of chloride anion by nitrate.
METHODS: Isolated perfused (Langendorff mode) rat hearts (n = 12 per group) were subjected to 30 min global or regional ischaemia. Ventricular arrhythmia incidence during ischaemia and during reperfusion were related to the size of the involved region. The modified model of global ischaemia employed right intra-atrial superfusion to maintain normal sinus rate and 1:1 atrioventricular (AV) conduction.
RESULTS: Sham ligation, low left coronary ligation, high left coronary ligation, and global ischaemia produced, as a percentage of total ventricular weight, 0%, 21.0(SEM 0.8)%, 47.0(1.0)%, and 100% regions of ischaemia (occluded zones). Heart rates were similar in each group and AV block did not occur. The incidences of ischaemia induced ventricular fibrillation (VF) were 0, 17, 75, and 17% with increasing occluded zone sizes. Incidences of reperfusion induced VF were 0, 8, 92, and 92% respectively. The antiarrhythmic action of substitution of extracellular chloride by nitrate, previously shown using models of regional ischaemia, was confirmed in the modified global ischaemia model.
CONCLUSIONS: These findings strongly support the theory that current of injury between ischaemia and adjacent non-ischaemic zones is necessary for initiation of ischaemia induced VF, since susceptibility was maximal when ischaemic and uninvolved regions were equivalent in size (and the scope for injury current was maximal) whereas susceptibility was negligible when scope was minimal. In contrast, reperfusion induced VF appears to depend only on the presence and amount of reperfused tissue, indicating that flow of injury current between involved and uninvolved tissue is unnecessary for its initiation. Discrimination of the mechanism of action of antiarrhythmic interventions may be possible since drugs effective solely via amelioration of flow of injury current (or incrementation of collateral flow) will not influence arrhythmias in this model. Modification of injury current and collateral flow do not appear to contribute to the antiarrhythmic action of substitution of extracellular chloride by nitrate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638559     DOI: 10.1093/cvr/26.4.309

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

1.  Contractile function assessment by intraventricular balloon alters the ability of regional ischaemia to evoke ventricular fibrillation.

Authors:  Catherine D E Wilder; Radwa Masoud; Duygu Yazar; Brett A O'Brien; Thomas R Eykyn; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2015-12-04       Impact factor: 8.739

2.  The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

Authors:  K E Baker; L M Wood; M Whittaker; M J Curtis
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 4.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

Authors:  Ellen Andrag; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

7.  Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

Authors:  Kathryn E Baker; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

8.  Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.

Authors:  Hugh Clements-Jewery; Ellen Andrag; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

9.  Facilitation of ischaemia-induced ventricular fibrillation by catecholamines is mediated by β1 and β2 agonism in the rat heart in vitro.

Authors:  Catherine D E Wilder; Nikoleta Pavlaki; Tutku Dursun; Paul Gyimah; Ellice Caldwell-Dunn; Antonella Ranieri; Hannah R Lewis; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

10.  Characterisation of mexiletine's translational therapeutic index for suppression of ischaemia-induced ventricular fibrillation in the rat isolated heart.

Authors:  Louise M Hesketh; Catherine D E Wilder; Niraja N Ranadive; Georgia Lytra; Patrisia Qazimi; Jade S Munro; Nakita Ahdi; Michael J Curtis
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.